摘要:
This invention provides a compound of the formula (I): a pharmaceutically acceptable salt or solvate thereof, wherein R1 is substituted or unsubstituted alkyl or the like, R2 is hydrogen or substituted or unsubstituted alkyl, Ring A is monocyclic or bicyclic aromatic heterocycle, R3 is substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl or substituted or unsubstituted heterocycle, R4 is halogen, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl or the like, m is an integer between 0 and 2, n is an integer between 0 and 5, R is halogen, oxo, cyano, nitro, substituted or unsubstituted alkyl or the like, and p is an integer between 0 and 2 as novel compounds having NPY Y5 antagonistic activity.
摘要:
A process for producing an aqueous solution of doripenem while decomposition of doripenem by heat is suppressed is found out.It was found out that decomposition of doripenem by heat can be suppressed by continuous heating an aqueous suspension of doripenem, and it was found out that an aqueous solution of doripenem can be produced.
摘要:
The present invention discloses novel cyclohexane derivatives having NPY Y5 receptor antagonistic activity. Specifically, the present invention discloses a compound represented by the formula (I), or a pharmaceutically acceptable salt or a solvate thereof: wherein A is substituted or unsubstituted aryl or heterocyclyl; a combination of X and Y is a combination selected from (X, Y)═(C(═O)N(R1), C(═O)N(R2)), (C(═O)N(R1), imidazole-1,3-diyl), (N(R1), C(═O)N(R2)), (O, C(═O)N(R2)), (C(R3)(R4), N(R2)) or (a single bond, C(═O)N(R2)); R1, R2 and R3 are independently hydrogen or substituted or unsubstituted alkyl; R5 is substituted or unsubstituted aryl or heterocyclyl; R6 is halogen, oxo, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryloxy; m is 0 or 1; and n is an integer of 0 to 5; and B is aromatic carbocycle, monocyclic heterocycle or fused bicyclic heterocycle.
摘要:
Disclosed is a novel compound having an NPY Y5 receptor antagonistic activity.A compound represented by the formula: its pharmaceutically acceptable salt or solvate thereof, wherein X is hydrogen or the like, Y is a group of the formula: Z is —NR7— or the like, R1 is hydrogen or the like, R2 and R3 are each independently hydrogen or the like, n is 0 or 1, p is 0 to 6.
摘要:
Compounds having an activity to enhance the expression of apoAI are provided. Compounds of formula (I): in which Ar1 and Ar2 are independently a phenyl, naphthyl, or monocyclic or bicyclic aromatic heterocyclic group, which may be optionally substituted; —X— is —N═CZ2—, —CY2═CZ2—, —CY2Y3—CHZ2—, —S—, —O—, or the like; Y1, Y2, Y3, Z1 and Z2 are independently a hydrogen, a halogen, a lower alkyl, a phenyl, or the like; Z1 and Z2 may be independently a linker group that may combine with Ar2 and Ar1 to form a condensed ring; m is 0 or 1, and n is 0 to 2; a prodrug thereof, a pharmaceutically acceptable salt or solvate thereof; are disclosed.
摘要:
The present invention provides Cephem compounds which have a wide antimicrobial spectrum and have potent antimicrobial activity against beta-lactamase producing Gram negative bacteria as follows:A compound of the formula: wherein, X is N, CH or C—Cl; T is S or the like; A and G are lower alkylene or the like; B is a single bond or the like; D is a single bond, —NR7—, —CO—, —CO—NR7—, —NR7—CO—, —NR7—CO—NR7—, or the like; E is optionally substituted lower alkylene; F is a single bond or optionally substituted phenylene; R3, R4, R5 and R6 each is independently hydrogen, halogene, nitrile, or the like; or an ester, a compound protected at the amino on the ring in the 7-side chain, a pharmaceutically acceptable salt, or a solvate thereof.
摘要翻译:本发明提供了具有广泛抗微生物谱并且对产生β-内酰胺酶的革兰氏阴性细菌具有强效抗微生物活性的Cephem化合物,如下式所示:其中X是N,CH或C-Cl; T是S等; A和G是低级亚烷基等; B是单键等; D是单键,-NR 7 - , - CO - , - CO-NR 7 - , - NR 7 -CO-, - NR 7 -CO-NR 7 - 等; E是任选取代的低级亚烷基; F是单键或任选取代的亚苯基; R 3,R 4,R 5和R 6各自独立地为氢,卤素,腈等; 或酯,在7-侧链的环上的氨基保护的化合物,其药学上可接受的盐或其溶剂合物。
摘要:
A tablet characterized by comprising 5-methyl-1-phenyl-2-(1H)-pyridone as the main ingredient and, based on the main ingredient, 10 to 50 wt. % excipient, 5 to 40 wt. % disintegrator, 1 to 10 wt. % binder, 0.5 to 5 wt. % lubricant, 2 to 6 wt. % coating basis, and 0.05 to 3 wt. % light-shielding agent, wherein the odor or bitterness of the 5-methyl-1-phenyl-2-(1H)-pyridone is masked and the light stability is improved.
摘要:
A compound having HIV Integrase Inhibitory activity of the formula: (wherein: R1 is optionally substituted aralkyl; R2 and R3 are each independently hydrogen, optionally substituted alkyl, optionally substituted amino, optionally substituted alkenyl or optionally substituted alkoxy (provided that each substituent for “optionally substituted” is a noncyclic group); R4 is hydrogen, optionally substituted carboxy, optionally substituted formylamino, optionally substituted carbamoyl, optionally substituted amino (provided that a substituent on amino in “optionally substituted formylamino”, “optionally substituted carbamoyl” and “optionally substituted amino” may form an optionally-substituted N-atom containing heterocyclic ring together with an adjacent N atom), optionally substituted alkyl, optionally substituted alkenyl, optionally substituted aryl, or optionally substituted heteroaryl) or a salt thereof.
摘要翻译:具有下式的HIV整合酶抑制活性的化合物:其中:R 1为任选取代的芳烷基; R 2和R 3各自独立地为氢,任选取代的烷基,任选取代的氨基,任选取代的烯基或任选取代的烷氧基(条件是每个取代基为“ 任选取代的“是非环基团); R 4是氢,任选取代的羧基,任选取代的甲酰氨基,任选取代的氨基甲酰基,任选取代的氨基(条件是在”任选取代的甲酰氨基“中的氨基上的取代基,”任选取代的氨基甲酰基“ 取代的氨基“可以与相邻的N原子一起形成任选取代的含有N原子的杂环,任选取代的烷基,任选取代的烯基,任选取代的芳基或任选取代的杂芳基)或其盐。
摘要:
Disclosed are process for producing a compound having NPYY5 receptor antagonism and useful crystals.A process for producing a compound represented by the formula (IV): wherein R1 is substituted or unsubstituted alkyl, R2 is substituted or unsubstituted alkyl, and n is 1 or 2, or the like, which comprises reacting a compound represented by the formula (II): wherein R1 and n are as defined above, and X is a leaving group, or the like and a compound represented by formula (III): wherein R2 is as defined above, or the like.